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Volume 58, Number 1 Rockman 1195 years following endarterectomy. These results were based on pre-
dicted long-term mortality. The current study uses actual mortality
and found that 18% of patients die within 5 years following endar-
terectomy. In both studies, incidence of postoperative stroke,
death, and myocardial infarction were also higher in patients
deﬁned as high risk. Overall, the results from these two separate
databases gave quite similar results.
Regarding your second question about late survival, all of the
data from VSGNE were linked to Social Security Death Index to
determine mortality for this study.
Dr Jacob Schneiderman (Ramat Gan, Israel). In your
presentation, you don’t consider carotid plaque composition as
a risk factor. If you were given the information that a 60% stenos-
ing internal carotid artery plaque in an asymptomatic patient has
a giant vulnerable component, namely a sizable necrotic core
with a thin ﬁbrous cap, would you consider this rupture-prone pla-
que as risk-full, thus necessitating carotid endarterectomy?
Dr Wallaert. Yes, I probably would consider that a high-risk
patient and would certainly factor those details into my decision to
operate or not for that individual. Unfortunately, this study uses
registry data that do not include measures such as the plaque char-
acteristics you described. Therefore, we were unable to account for
such variables in our analysis.
Dr William Jordan (Birmingham, Ala). I actually have some
disagreement with your conclusions speciﬁcally relative to your
high-risk cohort. I think you’re looking at the glass as half empty
instead of half full. Speciﬁcally, while you’ve identiﬁed this high-
risk group after the operation, could their survival be improved if
we directed more efforts on treating their medical disease? Stated
differently, I don’t believe the operation itself is the incident thatcauses the decreased survival; potentially, they might still beneﬁt
from the carotid repair if we can improve their medical therapy.
Can you comment?
Dr Wallaert. I agree. I don’t believe that operation itself is
responsible for reduced long-term survival in these high-risk
patients. I do believe, however, that it is our responsibility as
surgeons to take into consideration patient characteristics that
may make an individual less likely to beneﬁt from an operation
because he or she has medical comorbidities that will reduce his
or her lifespan and thus their opportunity to beneﬁt from stroke
prevention provided by an endarterectomy.
We recognize that our deﬁnition of poor long-term survival
or “inappropriate” is somewhat arbitrary, and many would argue
that a 50% 5-year survival is perfectly reasonable. I think that
deﬁnition of appropriateness is going to vary based on the indi-
vidual patient and his or her surgeon. Ultimately, it’s going to
come down to you, your patient, and a discussion about that
individual’s risk of postoperative mortality or stroke, as well as
their long-term chance of surviving to beneﬁt from a durable
repair.
Dr Jordan. Can your group then improve on the medical
therapy afterwards? Potentially, if we did a better job of taking
care of heart disease or lung disease, then they might have better
long-term survival.
Dr Wallaert. That’s certainly a consideration and I agree that
optimizing medical management of patients’ comorbidities, preop-
eratively and postoperatively, is critical. Unfortunately, we don’t
have data to suggest whether we are doing a good job of this or
not, so I can’t comment on the effect improved medical manage-
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ness of performing prophylactic interventions on patients with severe
asymptomatic carotid artery atherosclerotic plaque to prevent future
strokes. Prophylactic carotid endarterectomy (CEA) has been
demonstrated in several randomized, prospective trials to provide
superior stroke prevention compared with contemporaneous
medical therapies in patients with severe carotid artery stenosis.
However, ongoing current discussions have focused on the premise
that the incidence of ischemic stroke may be decreasing and the
hypothesis that improved pharmacologic therapies, such as statin
medications, may be responsible for the decreasing stroke rate.
If one were a proponent of these hypotheses, it would be natural
to conclude that the risk-beneﬁt balancewith regard to surgical treat-
ment of asymptomatic severe carotid artery atherosclerosis might
have indeed tipped toward the medical therapy side of the seesaw.
Nevertheless, stroke remains the fourth leading cause of death
in the United States and the leading cause of long-term disability
and institutionalization. Stroke represents a major worldwide
patient and economic burden. The treatment of stroke, once it
has occurred, is generally unsuccessful. Clearly, all physicians would
be eager for improved tools to designate those patients at highest
risk for stroke as well as for enriched stroke-prevention strategies
and methods. With regard to prophylactic carotid endarterectomy
(CEA) in asymptomatic patients, knowledge about the patient’s
long-term survival is critical to properly evaluate whether a patient
will derive potential beneﬁt from prophylactic surgical intervention.
In this regard, the current study from the Vascular Study
Group of New England provides important data for the clinician
who evaluates patients with carotid artery disease. A large cohort
of asymptomatic patients who underwent CEA was evaluated,
and the perioperative stroke and mortality rates were extremely
low. More than 80% of the patients who underwent CEA achieved
5-year survival after their surgery. On the basis of randomized,
prospective data, this should theoretically be long enough to attainstroke-prevention beneﬁt in appropriately selected asymptomatic
patients. A patient should probably not be considered for pro-
phylactic CEA if his or her individual life expectancy is felt to
be <3 years.
However, 5% of the patient cohort was deemed to be at “high
risk” for early death because of comorbid conditions; only 51% of
patients in this category would be expected to achieve 5-year
survival. In addition, 68% of patients who underwent CEA were
deemed “moderate risk,” and only 80% of the patients in this cate-
gory would be expected to achieve 5-year survival. Clearly, there is
room for improvement in patient selection in this regard.
The major risk factors for early mortality included advanced
age $80 years (hazard ratio, 3.94) and dialysis-dependent renal
failure (hazard ratio, 3.41); these are not unexpected ﬁndings.
Unfortunately, the current report is somewhat less successful in
discriminating the relative contribution of more “minor” risk
factors for death, including congestive heart failure, chronic
obstructive pulmonary disease, insulin-dependent diabetes, and
the degree of contralateral carotid artery stenosis. Most patients
who are evaluated for asymptomatic carotid artery disease will be
aged <80 years and not in dialysis-dependent failure; most will
also likely have at least one “minor” risk for early mortality, placing
them in the “moderate-risk” category according to the risk strati-
ﬁcation system derived by the authors.
Nevertheless, the current data do provide a valid framework
for clinicians to contemplate when choosing appropriate asymp-
tomatic patients for CEA. In addition to considering the degree
of stenosis, other anatomic and morphologic characteristics,
and the individual patient’s risk of perioperative complications after
surgery, it is critical for the surgeon to weigh the patient’s long-term
survival in order to achieve an appropriate stroke-prevention
beneﬁt. Certainly, patients deemed at “high risk” for early mortality
should probably not be considered for prophylactic CEA, and
patients at “moderate risk” need to be carefully considered.
